[ad_1]
Monoclonal antibody treatment for moderate Covid cycles has so far been able to provide some promising data. Regeneron combined the two antibodies “Regn10933” and “Regn10987” under the name “Regn-CoV2” and tested them on outpatients with mild to moderate illnesses. The result of an interim analysis a month ago: the viral load could be reduced, patients would have recovered faster.
The independent expert body IDMC now suggests a review of the test series. The exact reasons have not been revealed. The use of the antibody cocktail was initially limited. Patients who are dependent on oxygen ventilation should not currently receive the drug. The IDMC has received indications of an unfavorable risk-benefit ratio in this group of severely Sars-CoV-2 patients.
More data should now be collected before the drug can be reused in such patients. The US FDA is also involved. Use can be continued in patients who are not ventilated or who receive only a low oxygen supply.
Lilly also stops the antibody test
Lilly is also testing an antibody against Covid-19: “LY-CoV555” is the result of a collaboration with Abcellera. It originally comes from a blood sample from a cured Covid patient. It is a neutralizing monoclonal IgG1 antibody directed against the Sars-CoV-2 spike protein. In mid-October, however, Lilly announced that the antibody therapy test had been stopped. Again the reason was the recommendation of an independent panel of experts who, among other things, monitored patient safety during clinical trials.
Stay up to date and subscribe to the APOTHEKE ADHOC newsletter.
[ad_2]
Source link
